Rothschild & Co Redburn Forecasts Biogen Q1 Earnings

Biogen Inc. (NASDAQ:BIIB) – Stock analysts at Rothschild & Co Redburn issued their Q1 2026 earnings per share estimates for shares of Biogen in a research report issued to clients and investors on Tuesday, April 21st. Rothschild & Co Redburn analyst S. Chesney expects that the biotechnology company will post earnings of $3.51 per share for the quarter. Rothschild & Co Redburn has a “Neutral” rating and a $180.00 price objective on the stock. The consensus estimate for Biogen’s current full-year earnings is $15.77 per share. Rothschild & Co Redburn also issued estimates for Biogen’s Q2 2026 earnings at $4.73 EPS, Q3 2026 earnings at $4.42 EPS and Q4 2026 earnings at $3.33 EPS.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the previous year, the company posted $3.44 EPS. The business’s revenue for the quarter was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS.

Several other brokerages also recently issued reports on BIIB. Canaccord Genuity Group lifted their price objective on Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a research report on Wednesday, April 1st. Weiss Ratings restated a “hold (c-)” rating on shares of Biogen in a research report on Monday, December 29th. Citigroup dropped their target price on Biogen from $215.00 to $190.00 and set a “neutral” rating for the company in a research report on Monday, April 13th. Barclays began coverage on Biogen in a research report on Thursday, February 19th. They set an “equal weight” rating and a $185.00 target price for the company. Finally, Wolfe Research set a $231.00 target price on Biogen in a research report on Monday, February 9th. Fourteen equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $211.31.

Biogen Trading Down 1.9%

Shares of BIIB opened at $184.38 on Friday. The stock has a fifty day moving average price of $185.13 and a two-hundred day moving average price of $175.03. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. Biogen has a 52-week low of $115.25 and a 52-week high of $202.41. The company has a market cap of $27.06 billion, a price-to-earnings ratio of 20.93, a PEG ratio of 2.51 and a beta of 0.16.

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares in the company, valued at $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.18% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Biogen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BIIB. Reflection Asset Management bought a new stake in Biogen in the fourth quarter valued at about $25,000. WPG Advisers LLC increased its holdings in Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 117 shares during the last quarter. Accredited Wealth Management LLC increased its holdings in Biogen by 1,233.3% in the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 185 shares during the last quarter. First Horizon Corp bought a new stake in Biogen in the fourth quarter valued at about $30,000. Finally, WFA of San Diego LLC bought a new stake in Biogen in the second quarter valued at about $32,000. Institutional investors own 87.93% of the company’s stock.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen struck a China deal to develop felzartamab as a domestically produced anti‑CD38 therapy for multiple myeloma — this expands its China footprint and could open a meaningful growth market. Biogen seeks Darzalex rivalry in China for multiple myeloma with felzartamab deal
• Positive Sentiment: UBS upgraded Biogen, and JPMorgan raised its price target to $185 (still a Neutral rating) — these moves provide some analyst validation for the story but stop short of a full buy case. UBS upgrades Biogen (BIIB) JPMorgan raises price target
• Neutral Sentiment: Q1 earnings preview pieces highlight that new products (Skyclarys, Zurzuvae) are driving growth but legacy MS sales face competitive pressure — outcome of Q1 will be a key catalyst and remains uncertain. Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?
• Neutral Sentiment: Rothschild & Co Redburn issued EPS estimates and raised its price target to $180 while maintaining a Neutral rating — adds supply of modeled forecasts but not a bullish call. Rothschild & Co Redburn estimates and target
• Negative Sentiment: Short interest rose to ~4.41M shares as of April 15 (+15.4% vs. March 31), representing about 3.0% of float and a short‑interest ratio ~3.1 days — higher shorting can amplify downward pressure around weak news. (Note: an April 24 data point showing zero shares appears to be a reporting anomaly.)
• Negative Sentiment: Wolfe Research trimmed Q1 and Q2 EPS estimates (and trimmed Q2 guidance), signaling risk to near‑term earnings expectations and likely contributing to negative trading sentiment.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.